NCT03866993View on ClinicalTrials.gov

A Study of Anti-PD-1 AK105 in Patients With Metastatic Squamous Non-small Cell Lung Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

350

Participants

Timeline

Start Date

December 20, 2018

Primary Completion Date

October 8, 2020

Study Completion Date

January 14, 2022

Conditions
Lung Cancer Non-small Cell Stage IVSquamous Cell Lung Cancer
Interventions
BIOLOGICAL

AK105

IV infusion

DRUG

Paclitaxel

IV infusion

DRUG

Carboplatin

IV infusion

DRUG

Placebo

IV infusion

Trial Locations (2)

200025

Shanghai Chest Hospital, Shanghai

Unknown

Chinese PLA General Hospital, Beijing

Sponsors

Lead Sponsor

Akeso
All Listed Sponsors
collaborator

Akeso Tiancheng, Inc

OTHER

lead

Akeso

INDUSTRY

NCT03866993 - A Study of Anti-PD-1 AK105 in Patients With Metastatic Squamous Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter